Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study

Svanberg, Anncarin; Öhrn, Kerstin; Birgegård, Gunnar

doi:10.1016/j.ejon.2014.07.011

Cited by 26 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Study rinses were initiated following onset of OM, and all end points between the two groups were similar. Svanberg et al (2015) reported a randomised controlled open-abel trial of cryotherapy with or without Caphosol for prevention of OM in patients undergoing allogeneic HCT, with no differences in OM between the two groups.…”

Section: Discussionmentioning

confidence: 99%

“…The study by Wasko-Grabowska et al (2011) described one subject (1 out of 32, 3.1%) who had ‘problems with the taste' of Caphosol, but any potential impact on regimen compliance was not reported. The study by Svanberg et al (2015) reported one subject who stopped Caphosol rinses because of disagreeable taste. Of note, the study by Raphael et al (2014) was conducted in children aged 4 to 18 years randomised to NaCl 0.9% or Caphosol and reported that no patients dropped out because of intolerance/bad taste, although compliance was not described.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

et al. 2016

View full text Add to dashboard Cite

Background:The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT).Methods:This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0–10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3).Results:The study enrolled 220 participants with a median age of 13.7 years (range 4.0–21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups.Conclusions:Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Nonetheless, there are reports of symptomatic benefits for the other agents (Yuan and Sonis, 2014; Villa and Sonis, 2016). Caphosol, a remineralizing solution, has been tested in multiple, randomized, blinded trials of which the results do not generally support its efficacy for an OM indication (Rao et al, 2014; Svanberg et al, 2015; Wong et al, 2016; Treister et al, 2017). …”

Section: Management Of Gastrointestinal Mucositis: Current and Investmentioning

confidence: 99%

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

et al. 2017

View full text Add to dashboard Cite

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients’ related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.

show abstract

“…Of these, 2 RCTs [24,27] reported that SCPR was effective for the prevention of OM. A single RCT reported that it was ineffective [28]. This latter study compared a combination of SCPR and cryotherapy with cryotherapy alone.…”

Section: Supersaturated Calcium Phosphate Rinsementioning

confidence: 99%

Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements

Yarom

Hovan²,

Bossi

et al. 2019

Support Care Cancer

View full text Add to dashboard Cite

Purpose To update the clinical practice guidelines for the use of natural and miscellaneous agents for the prevention and/or treatment of oral mucositis (OM). Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible. Results A total of 78 papers were identified within the scope of this section, out of which 29 were included in this part, and were analyzed with 27 previously reviewed studies. A new Suggestion was made for oral glutamine for the prevention of OM in head and neck (H&N) cancer patients receiving radiotherapy with concomitant chemotherapy. The previous Recommendation against the use of parenteral glutamine for the prevention of OM in hematopoietic stem cell transplantation (HSCT) patients was reestablished. A previous Suggestion for zinc to prevent OM in H&N cancer patients treated with radiotherapy or chemoradiotherapy was reversed to No Guideline Possible. No guideline was possible for other interventions. Conclusions Of the vitamins, minerals, and nutritional supplements studied for the management of OM, the evidence supports a Recommendation against parenteral glutamine in HSCT patients and a Suggestion in favor of oral glutamine in H&N cancer patients for the management of OM.

show abstract

Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study

Cited by 26 publications

References 18 publications

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements

Contact Info

Product

Resources

About